Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe golden dose of Mounjaro refers to 5mg — and yes, 5mg is a full, licensed therapeutic dose, not a halfway point or a stepping stone in disguise. The 2.5mg starting pen exists purely to help your body adjust; once you move to 5mg, you are on an active treatment dose. That said, 'golden dose' is informal language the Mounjaro community settled on, not a clinical term. These are prescription-only medicines, and the right dose for you is decided by a prescriber who reviews your individual health picture — not by a phrase doing the rounds online.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro's titration schedule starts at 2.5mg, but that first pen has a specific, limited purpose: settling your digestive system before the medicine does its main job. Nausea, constipation and other gastrointestinal effects are most pronounced when tirzepatide is introduced, and a lower opener gives your body four weeks to adjust. Think of it as calibration rather than treatment. The NHS medicines page for tirzepatide describes the 2.5mg dose in exactly these terms, a starting dose to reduce the risk of side effects, with dose increases following on clinical advice.
This matters because some people arrive at 5mg already half-convinced they are still on a sub-therapeutic dose. They are not. The moment your prescriber moves you up, you are on a dose that was tested and licensed in its own right. That shift is real, and the appetite change many people describe reflects it.
Your prescriber or the Patient Information Leaflet should be your guide on when and whether to increase, it is not a decision to make based on peer forums, however well-meaning the advice there.
In the UK, Mounjaro is licensed in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. Each is a complete, once-weekly dose. None of them is a fraction of another. 5mg is not half a dose by any definition, it is one of the six authorised treatment options, delivered in its own KwikPen. The 5mg 'golden dose' in practice is discussed in more detail on a dedicated page, but the regulatory point is simple: 5mg was evaluated independently in clinical trials and approved on that basis.
The 'golden dose' label emerged because a meaningful number of people report that 5mg is the point where appetite suppression becomes clearly noticeable without feeling overwhelming. That is a lived experience worth knowing about. It is also not universal: some people find the same effect at 7.5mg or even 10mg; others are more sensitive and notice it from 2.5mg. Biology varies, which is precisely why a prescriber reviews the picture rather than a formula.
If you are curious about what constitutes a full dose of Mounjaro across the whole range, that page covers the licensed strengths in full.
The phrase 'golden dose' spread through UK weight-loss forums and social media. It captures a real pattern (a dose at which many people feel the medicine shift noticeably) but it carries some risks if taken too literally. Treating 5mg as an endpoint, or assuming that staying there indefinitely is always the right call, removes the prescriber from a decision that properly belongs to them. Equally, expecting a golden-dose moment that never arrives at 5mg can be discouraging if your biology means the effect builds more slowly.
NICE's appraisal of tirzepatide, TA1026, notes that treatment should be reviewed if less than five per cent weight loss is achieved after six months at the highest tolerated dose. That framing is important: the licensed dose range goes to 15mg, and a prescriber's job is to find the dose that works for you within that range, not to park you at the community's favourite number.
None of this diminishes the 5mg experience for the many people it applies to. It simply puts a community term back in its proper context: a useful shorthand, not a clinical instruction.
If you are already on Mounjaro and wondering whether your current dose is right, the conversation belongs with your prescriber. Dose increases should rest on clinical evidence, not on forum reassurance that a higher rung is 'where the magic happens'. If you are considering starting treatment and want to understand the golden dose concept before your first consultation, that is a reasonable thing to bring to the appointment.
At some point you may also wonder about practical details (how the doses compare in volume or click count) and pen volume and what each click delivers are covered separately if that helps you feel more confident before your first injection.
Cost is sometimes what drives people to research specific doses rather than the full range. If that is part of your thinking, the cost of Mounjaro in the UK page is an honest starting point. Bear in mind that price varies by dose and provider, and a legitimate supply always involves a prescription following clinical assessment, not just the cheapest listing on a search page.
If you are new to all of this, the Mounjaro overview covers the full picture from mechanism to eligibility, and checking your eligibility with our prescribers is the straightforward next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.